Data / Drug companies / CivicaScript LLC
CivicaScript LLC: 27 products in the FDA NDC directory, labeler code 82249
CivicaScript LLC (labeler code 82249) lists 27 products in the FDA National Drug Code Directory, covering 11 finished drugs by generic name. By type: 27 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on November 2, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 82249
- Products in commercial distribution
- 27
- Packages
- 32
- Finished drugs by generic name
- 11
- Prescription products
- 27
- Over the counter products
- 0
- Flagged as original packager
- 23 of 23 products that carry the flag
- Started marketing in the last 12 months
- 13
- Earliest marketing start
- November 23, 2018
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 27 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 27 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Temozolomide | 6 | 12 |
| Everolimus | 4 | 15 |
| Droxidopa | 3 | 15 |
| Teriflunomide | 2 | 17 |
| Imatinib mesylate | 2 | 17 |
| Dimethyl fumarate | 2 | 20 |
| Capecitabine | 2 | 19 |
| Abiraterone acetate | 2 | 22 |
| Pirfenidone | 2 | 26 |
| Fingolimod | 1 | 18 |
| Dalfampridine | 1 | 11 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule | 10 | 37% |
| Tablet, film coated | 8 | 29.6% |
| Tablet | 6 | 22.2% |
| Capsule, delayed release | 2 | 7.4% |
| Tablet, film coated, extended release | 1 | 3.7% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Pirfenidone | 82249-116 | Tablet, film coated | Generic drugs (ANDA) | November 2, 2026 |
| Pirfenidone | 82249-115 | Tablet, film coated | Generic drugs (ANDA) | November 2, 2026 |
| Teriflunomide | 82249-112 | Tablet, film coated | Generic drugs (ANDA) | October 26, 2026 |
| Teriflunomide | 82249-111 | Tablet, film coated | Generic drugs (ANDA) | October 26, 2026 |
| Temozolomide | 82249-414 | Capsule | Generic drugs (ANDA) | August 10, 2026 |
| Temozolomide | 82249-412 | Capsule | Generic drugs (ANDA) | August 10, 2026 |
| Temozolomide | 82249-410 | Capsule | Generic drugs (ANDA) | August 10, 2026 |
| Temozolomide | 82249-408 | Capsule | Generic drugs (ANDA) | August 10, 2026 |
| Temozolomide | 82249-406 | Capsule | Generic drugs (ANDA) | August 10, 2026 |
| Temozolomide | 82249-404 | Capsule | Generic drugs (ANDA) | August 10, 2026 |
| Imatinib mesylate | 82249-021 | Tablet, film coated | Generic drugs (ANDA) | July 3, 2026 |
| Imatinib mesylate | 82249-020 | Tablet, film coated | Generic drugs (ANDA) | July 3, 2026 |
| Fingolimod | 82249-385 | Capsule | Generic drugs (ANDA) | June 1, 2026 |
| Dalfampridine | 82249-702 | Tablet, film coated, extended release | Generic drugs (ANDA) | July 21, 2025 |
| Capecitabine | 82249-210 | Tablet, film coated | Generic drugs (ANDA) | June 26, 2025 |
| Capecitabine | 82249-207 | Tablet, film coated | Generic drugs (ANDA) | June 26, 2025 |
| Dimethyl fumarate | 82249-747 | Capsule, delayed release | Generic drugs (ANDA) | June 11, 2025 |
| Dimethyl fumarate | 82249-745 | Capsule, delayed release | Generic drugs (ANDA) | June 11, 2025 |
| Droxidopa | 82249-554 | Capsule | Generic drugs (ANDA) | March 3, 2025 |
| Droxidopa | 82249-552 | Capsule | Generic drugs (ANDA) | March 3, 2025 |
| Droxidopa | 82249-551 | Capsule | Generic drugs (ANDA) | March 3, 2025 |
| Yulithira | 82249-613 | Tablet | Generic drugs (ANDA) | March 5, 2021 |
| Yulithira | 82249-612 | Tablet | Generic drugs (ANDA) | March 5, 2021 |
| Yulithira | 82249-611 | Tablet | Generic drugs (ANDA) | March 5, 2021 |
| Yulithira | 82249-610 | Tablet | Generic drugs (ANDA) | March 5, 2021 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.